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Study design
A case series of patients at a single centre was used to compare simple transfusion with or without chelation therapy to erythrocytapheresis. The duration of follow-up was not reported.
Analysis of effectiveness
The primary health outcome used was serum ferritin levels which provide an estimate of total body iron levels. These were measured approximately every 3 months, using the Imx microparticle enzyme immunoassay.
Effectiveness results
Three patients who received erythrocytapheresis in addition to chelation therapy (deferoxamine) showed a significant decrease in serum ferritin levels. One discontinued chelation therapy due to a decline in serum ferritin to 600 ng/ml. Four patients, who did not receive chelation therapy due to allergy or non-compliance, underwent erythrocytapheresis for up to 20 months. Three of these stabilised their serum ferritin levels, and one decreased his serum ferritin levels significantly. The remaining three received no chelation therapy and started erythrocytapheresis therapy soon after a cerebral vascular accident. Their serum ferritin levels remained at a level below that necessitating chelation therapy.
Clinical conclusions
Erythrocytapheresis is a safe method of exchange transfusion which has been proven to be efficacious in small paediatric patients.
Measure of benefits used in the economic analysis
No specific measure of benefit was used in the analysis.
Direct costs
Costs were not discounted. Quantities were not reported separately from the prices. The costs measured were mean annual charges. The charges for simple transfusion therapy included a clinic fee, an equipment fee (filter, tubing, catheters), and a blood bank fee (type and cross, processing). The charges for chelation therapy varied among the home health agencies used. The mean annual charge for erythrocytapheresis included a clinic fee, a blood bank fee, and an apheresis fee. No specific price date was reported.
